October 23, 2024
Home-based transcranial direct current stimulation (tDCS) with real-time remote supervision was associated with significantly greater symptom improvement and higher clinical remission rates than sham treatment in […]
October 22, 2024
Among Canadian politicians, there is a rising interest in the involuntary treatment of homeless patients with episodes of mental illness and substance abuse. Experts, however, say […]
October 18, 2024
The European Medicines Agency has recommended granting marketing authorization for a new hybrid formulation of buprenorphine as a substitution treatment of opioid drug dependence. Buprenorphine Neuraxpharm […]
October 18, 2024
A new study provides more evidence that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) used to treat diabetes and obesity could be repurposed for opioid use […]
October 17, 2024
TOPLINE: Conversion practices targeting gender identity or sexual orientation are associated with increased depression, posttraumatic stress disorder (PTSD), and suicidality in LGBTQ+ adults, a new study […]
October 17, 2024
It has been 24 years since a pharmaceutical was last approved for posttraumatic stress disorder (PTSD). The condition is notoriously difficult to treat, with up to […]
October 15, 2024
TOPLINE: Bright light therapy (BLT) is associated with a 41% remission rate in patients with nonseasonal depressive disorders, significantly higher than the remission rates reported with […]
October 15, 2024
As at-home, do-it-yourself (DIY) brain stimulation devices like transcranial direct current stimulation (tDCS) gain popularity for common psychiatric conditions like depression, anxiety, and posttraumatic stress disorder […]
October 15, 2024
TOPLINE: Deprescribing antihypertensive medications is associated with a 12% lower likelihood of cognitive decline in older nursing home residents, a new study suggests. The association was […]